$INO Cashflow Statement | Understand Stock

$INO

$0.89 +$0.02 (2.32%) Close

$INO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization of intangible assets
Amortization of operating lease right-of-use assets
Change in fair value of derivative liability
Change in fair value of common stock warrant liabilities
Impairment of goodwill
Impairment of intangible assets
Deferred taxes
Non-cash stock-based compensation
Amortization of premiums on investments
Non-cash interest on senior convertible notes
Amortization of discounts on investments
Loss on sales of short-term investments
Settlement of receivable with shares of common stock from affiliated entity (PLS)
Gain on deconsolidation of Geneos
Gain on remeasurement of investment in Geneos
Net gain on disposal of fixed assets
(Gain) loss on equity investment in affiliated entity
Share of net loss in Geneos
Gain (loss) on extinguishment of convertible bonds and senior notes
Net unrealized gain on available-for-sale equity securities
Tax benefit from other unrealized gains on short-term investments
Unrealized transaction (gain) loss on foreign-currency denominated debt

Changes in operating assets and liabilities:
Accounts receivable, including from affiliated entities
Accounts receivable from affiliated entities
Prepaid expenses and other current assets, including from affiliated entity
Prepaid expenses and other current assets from affiliated entities
Other assets
Accounts payable and accrued expenses, including due to affiliated entity
Accrued clinical trial expenses
Accounts payable and accrued expenses due to affiliated entities
Deferred revenue, including from affiliated entity
Deferred revenue from affiliated entities
Operating lease right-of-use assets and liabilities, net
Grant funding liability, including from affiliated entity
Grant funding liability from affiliated entities
Other liabilities

Net cash used in operating activities
Cash flows from investing activities:
Purchases of investments
Proceeds from sale of investments
Proceeds from maturity of investments
Purchases of capital assets
Proceeds from sale of investment of GeneOne
Decrease in cash resulting from the deconsolidation of Geneos
Proceeds from sale of capital assets
Investment in Geneos
Net cash provided by investing activities

Cash flows from financing activities:
Proceeds from issuances of convertible senior notes and convertible bonds
Costs related to issuances of convertible senior notes and convertible bonds
Repayment of convertible senior notes
Proceeds from issuance of pre-funded warrants, net of issuance costs
Proceeds from issuance of warrants, net of issuance costs
Pre-Funded Warrants
Warrants to purchase common stock
Total proceeds from issuance of warrants, net of issuance costs
Proceeds from issuance of common stock, net of issuance costs
Proceeds from warrant exercises
Proceeds from stock option exercises
Taxes paid related to net share settlement of equity awards
Acquisition of non-controlling interest
Proceeds from Geneos issuance of note payable
Net cash provided by financing activities

Effect of exchange rate changes on cash and cash equivalents
(Decrease) Increase in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Supplemental disclosure:
Amounts accrued for purchases of fixed assets
Interest paid
Change in prepaid expenses and other current assets related to fixed assets
Equity component of issuance of convertible notes
Right-of-use assets obtained in exchange for lease obligations
Issuance of common stock as part of litigation settlement

Comments